p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator.

Iron is involved in essential biochemical reactions ranging from respiration to DNA synthesis. Consequently, iron deprivation has been proposed as a strategy for inhibition of tumor cell growth. We recently described a novel iron chelator, tachypyridine [N,N',N"-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane], and demonstrated that it not only inhibited growth of cultured tumor cells, but was actively cytotoxic. Here we explore the mechanisms underlying tachpyridine cytotoxicity. Using several criteria, including time-lapse video microscopy, DNA staining and TUNEL assays, tachpyridine was shown to specifically induce apoptotic cell death. Further, unlike numerous cytotoxic chemotherapeutic drugs which induce apoptosis by activating p53-dependent pathways, tachpyridine-mediated cell death did not require p53 activation. Although immunoblotting revealed rapid accumulation of p53 following treatment with tachpyridine, p21(WAF1) was not induced. Further, neither cytotoxicity nor apoptosis required p53. p53 null human lung cancer H1299 cells transfected with an ecdysone-inducible p53 exhibited equivalent sensitivity to tachpyridine in the presence and absence of p53, demonstrating the lack of requirement for p53 in an isogenic cell system. Further, time-lapse video microscopy and TUNEL assays demonstrated that both p53 null and p53 wild-type cells underwent apoptotic cell death in response to tachpyridine. In addition, in 55 human cancer cell lines the mean GI(50) of tachpyridine in cells with mutant p53 was virtually identical to the GI(50) in cells with wild-type p53. These results demonstrate that tachpyridine initiates an apoptotic mode of cell death that does not require functional p53. Since over 50% of human tumors contain a functionally defective p53 that reduces sensitivity to commonly used chemotherapeutic agents, such as etoposide and cisplatin, the ability of tachpyridine to induce apoptosis independently of p53 may offer an advantage in anti-tumor therapy.

[1]  Yoichi Taya,et al.  Regulation of p53 by Hypoxia: Dissociation of Transcriptional Repression and Apoptosis from p53-Dependent Transactivation , 2001, Molecular and Cellular Biology.

[2]  Catherine Méplan,et al.  Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells , 2000, Oncogene.

[3]  G. Lescoat,et al.  Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. , 2000, Carcinogenesis.

[4]  K. Vousden,et al.  Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.

[5]  M. Willingham Cytochemical Methods for the Detection of Apoptosis , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  M. Ishidate,et al.  APOPTOSIS DURING IRON CHELATOR‐INDUCED DIFFERENTIATION IN F9 EMBRYONAL CARCINOMA CELLS , 1999, Cell biology international.

[7]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. , 1999, Blood.

[8]  K. Vousden,et al.  Mechanisms of p53-mediated apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.

[9]  M. Gassmann,et al.  Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. , 1998, Cancer research.

[10]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[11]  Moshe Oren,et al.  Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs , 1998, Oncogene.

[12]  M. Brechbiel,et al.  Novel iron complexes and chelators based on cis,cis-1,3,5-triaminocyclohexane: iron-mediated ligand oxidation and biochemical properties , 1998, JBIC Journal of Biological Inorganic Chemistry.

[13]  M. Brechbiel,et al.  Tumor cell cytotoxicity of a novel metal chelator. , 1998, Blood.

[14]  K. Vousden,et al.  Characterization of Structural p53 Mutants Which Show Selective Defects in Apoptosis but Not Cell Cycle Arrest , 1998, Molecular and Cellular Biology.

[15]  L. Neckers,et al.  Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.

[16]  D. Naidoo,et al.  Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. , 1998, Cancer research.

[17]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[18]  S. Nagata,et al.  Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis , 1998, Nature.

[19]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[20]  D. Givol,et al.  Induced p 53 expression in lung cancer cell line promotes cell senescence and di erentially modi ® es the cytotoxicity of anti-cancer drugs , 1998 .

[21]  D. Richardson Potential of iron chelators as effective antiproliferative agents. , 1997, Canadian journal of physiology and pharmacology.

[22]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[23]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[24]  Cynthia A. Schandl,et al.  Major DNA Fragmentation Is a Late Event in Apoptosis , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.

[26]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[27]  Yi Sun,et al.  Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound , 1997, Oncogene.

[28]  J. Kemp,et al.  Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. , 1997, Histology and histopathology.

[29]  J. Kemp,et al.  Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. , 1997, Pathobiology : journal of immunopathology, molecular and cellular biology.

[30]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[31]  R. Evans,et al.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Brechbiel,et al.  An improved synthesis of cis,cis-1,3,5-triaminocyclohexane. Synthesis of novel hexadentate ligand derivatives for the preparation of gallium radiopharmaceuticals , 1996 .

[33]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[34]  R. Cozza,et al.  Role of deferoxamine in tumor therapy. , 1996, Acta haematologica.

[35]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.

[36]  J. Kemp,et al.  Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. , 1995, Cancer research.

[37]  R. Haq,et al.  Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. , 1995, Experimental hematology.

[38]  A. Hoffbrand,et al.  Iron chelators induce apoptosis in proliferating cells , 1995, British journal of haematology.

[39]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[40]  D. Fisher Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[41]  P. Walker,et al.  Detection of the initial stages of DNA fragmentation in apoptosis. , 1993, BioTechniques.

[42]  P. Hainaut,et al.  Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. , 1993, Cancer research.

[43]  M. Fritsche,et al.  Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. , 1993, Oncogene.

[44]  R. Rubin,et al.  Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice , 1992, Cancer.

[45]  R. Hider,et al.  Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. , 1992, Cancer research.

[46]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[47]  J. Kemp,et al.  Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. , 1990, Blood.

[48]  A. Donfrancesco,et al.  Effects of a single course of deferoxamine in neuroblastoma patients. , 1990, Cancer research.

[49]  R. Hider,et al.  2 The development of iron chelating drugs , 1989 .

[50]  R. Hider,et al.  The development of iron chelating drugs. , 1989, Bailliere's clinical haematology.

[51]  H. Munro,et al.  Translation of ferritin light and heavy subunit mRNAs is regulated by intracellular chelatable iron levels in rat hepatoma cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Weinberg Iron withholding: a defense against infection and neoplasia. , 1984, Physiological reviews.

[53]  M. Freedman,et al.  Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. , 1984, Blood.

[54]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[55]  W. Faulk,et al.  TRANSFERRIN AND TRANSFERRIN RECEPTORS IN CARCINOMA OF THE BREAST , 1980, The Lancet.